nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C19—Vismodegib—skin cancer	0.139	0.221	CbGbCtD
Sitaxentan—CYP2C9—Vismodegib—skin cancer	0.116	0.184	CbGbCtD
Sitaxentan—CYP3A4—Imiquimod—skin cancer	0.0971	0.154	CbGbCtD
Sitaxentan—CYP3A4—Temozolomide—skin cancer	0.0971	0.154	CbGbCtD
Sitaxentan—CYP3A4—Vismodegib—skin cancer	0.0673	0.107	CbGbCtD
Sitaxentan—CYP3A4—Vemurafenib—skin cancer	0.0532	0.0846	CbGbCtD
Sitaxentan—CYP2C9—Fluorouracil—skin cancer	0.0411	0.0654	CbGbCtD
Sitaxentan—CYP3A4—Docetaxel—skin cancer	0.0183	0.029	CbGbCtD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.00202	0.0896	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide GPCRs—MC1R—skin cancer	0.00149	0.0661	CbGpPWpGaD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.00144	0.0641	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide GPCRs—MC1R—skin cancer	0.00107	0.0473	CbGpPWpGaD
Sitaxentan—EDNRA—EGFR-dependent Endothelin signaling events—HRAS—skin cancer	0.000813	0.0361	CbGpPWpGaD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	0.000762	0.0338	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—MC1R—skin cancer	0.000701	0.0311	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Other—SMO—skin cancer	0.000611	0.0271	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000549	0.0244	CbGpPWpGaD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	0.000545	0.0242	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—MC1R—skin cancer	0.000502	0.0223	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—PTCH2—skin cancer	0.000495	0.022	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00047	0.0209	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000393	0.0174	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000361	0.016	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—MC1R—skin cancer	0.000358	0.0159	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—PTCH2—skin cancer	0.000354	0.0157	CbGpPWpGaD
Sitaxentan—Hepatobiliary disease—Temozolomide—skin cancer	0.000337	0.000968	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000337	0.0149	CbGpPWpGaD
Sitaxentan—Photosensitivity reaction—Fluorouracil—skin cancer	0.000336	0.000966	CcSEcCtD
Sitaxentan—Alopecia—Bleomycin—skin cancer	0.000335	0.000963	CcSEcCtD
Sitaxentan—Sinusitis—Temozolomide—skin cancer	0.000335	0.00096	CcSEcCtD
Sitaxentan—Dyspepsia—Imiquimod—skin cancer	0.000334	0.000959	CcSEcCtD
Sitaxentan—Decreased appetite—Imiquimod—skin cancer	0.00033	0.000947	CcSEcCtD
Sitaxentan—Infestation NOS—Fluorouracil—skin cancer	0.000329	0.000943	CcSEcCtD
Sitaxentan—Infestation—Fluorouracil—skin cancer	0.000329	0.000943	CcSEcCtD
Sitaxentan—Flushing—Dactinomycin—skin cancer	0.000328	0.000943	CcSEcCtD
Sitaxentan—Hypersensitivity—Vemurafenib—skin cancer	0.000328	0.000941	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Imiquimod—skin cancer	0.000328	0.000941	CcSEcCtD
Sitaxentan—Fatigue—Imiquimod—skin cancer	0.000327	0.000939	CcSEcCtD
Sitaxentan—Menopausal symptoms—Docetaxel—skin cancer	0.000326	0.000936	CcSEcCtD
Sitaxentan—Visual disturbance—Docetaxel—skin cancer	0.000325	0.000932	CcSEcCtD
Sitaxentan—Pain—Imiquimod—skin cancer	0.000324	0.000932	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Fluorouracil—skin cancer	0.000324	0.00093	CcSEcCtD
Sitaxentan—Renal impairment—Docetaxel—skin cancer	0.000323	0.000928	CcSEcCtD
Sitaxentan—Myocardial infarction—Fluorouracil—skin cancer	0.000322	0.000925	CcSEcCtD
Sitaxentan—Haemoglobin—Temozolomide—skin cancer	0.000322	0.000924	CcSEcCtD
Sitaxentan—Stomatitis—Fluorouracil—skin cancer	0.00032	0.000919	CcSEcCtD
Sitaxentan—Hepatitis—Temozolomide—skin cancer	0.00032	0.000919	CcSEcCtD
Sitaxentan—Haemorrhage—Temozolomide—skin cancer	0.00032	0.000919	CcSEcCtD
Sitaxentan—Conjunctivitis—Fluorouracil—skin cancer	0.000319	0.000917	CcSEcCtD
Sitaxentan—Asthenia—Vemurafenib—skin cancer	0.000319	0.000917	CcSEcCtD
Sitaxentan—Urinary tract disorder—Temozolomide—skin cancer	0.000316	0.000908	CcSEcCtD
Sitaxentan—Oedema peripheral—Temozolomide—skin cancer	0.000315	0.000905	CcSEcCtD
Sitaxentan—Cardiac failure—Docetaxel—skin cancer	0.000315	0.000905	CcSEcCtD
Sitaxentan—Urethral disorder—Temozolomide—skin cancer	0.000314	0.000901	CcSEcCtD
Sitaxentan—Alopecia—Dactinomycin—skin cancer	0.000313	0.000898	CcSEcCtD
Sitaxentan—Feeling abnormal—Imiquimod—skin cancer	0.000313	0.000898	CcSEcCtD
Sitaxentan—Epistaxis—Fluorouracil—skin cancer	0.00031	0.00089	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000309	0.0137	CbGpPWpGaD
Sitaxentan—Visual impairment—Temozolomide—skin cancer	0.000308	0.000886	CcSEcCtD
Sitaxentan—Sinusitis—Fluorouracil—skin cancer	0.000308	0.000885	CcSEcCtD
Sitaxentan—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000308	0.000883	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—RHOU—skin cancer	0.000307	0.0136	CbGpPWpGaD
Sitaxentan—Ill-defined disorder—Bleomycin—skin cancer	0.000306	0.00088	CcSEcCtD
Sitaxentan—Anaemia—Bleomycin—skin cancer	0.000305	0.000877	CcSEcCtD
Sitaxentan—Diarrhoea—Vemurafenib—skin cancer	0.000304	0.000874	CcSEcCtD
Sitaxentan—Migraine—Docetaxel—skin cancer	0.000303	0.00087	CcSEcCtD
Sitaxentan—Urticaria—Imiquimod—skin cancer	0.000301	0.000866	CcSEcCtD
Sitaxentan—Body temperature increased—Imiquimod—skin cancer	0.0003	0.000861	CcSEcCtD
Sitaxentan—Eye disorder—Temozolomide—skin cancer	0.000299	0.000859	CcSEcCtD
Sitaxentan—Tinnitus—Temozolomide—skin cancer	0.000298	0.000857	CcSEcCtD
Sitaxentan—Malaise—Bleomycin—skin cancer	0.000298	0.000855	CcSEcCtD
Sitaxentan—Cardiac disorder—Temozolomide—skin cancer	0.000297	0.000853	CcSEcCtD
Sitaxentan—Flushing—Temozolomide—skin cancer	0.000297	0.000853	CcSEcCtD
Sitaxentan—Haemoglobin—Fluorouracil—skin cancer	0.000296	0.000851	CcSEcCtD
Sitaxentan—Leukopenia—Bleomycin—skin cancer	0.000296	0.000849	CcSEcCtD
Sitaxentan—Rhinitis—Fluorouracil—skin cancer	0.000296	0.000849	CcSEcCtD
Sitaxentan—Haemorrhage—Fluorouracil—skin cancer	0.000295	0.000847	CcSEcCtD
Sitaxentan—Dizziness—Vemurafenib—skin cancer	0.000294	0.000845	CcSEcCtD
Sitaxentan—Angiopathy—Temozolomide—skin cancer	0.00029	0.000834	CcSEcCtD
Sitaxentan—Ataxia—Docetaxel—skin cancer	0.000289	0.000831	CcSEcCtD
Sitaxentan—Immune system disorder—Temozolomide—skin cancer	0.000289	0.00083	CcSEcCtD
Sitaxentan—Mediastinal disorder—Temozolomide—skin cancer	0.000288	0.000828	CcSEcCtD
Sitaxentan—Dehydration—Docetaxel—skin cancer	0.000286	0.000822	CcSEcCtD
Sitaxentan—Ill-defined disorder—Dactinomycin—skin cancer	0.000286	0.000821	CcSEcCtD
Sitaxentan—Anaemia—Dactinomycin—skin cancer	0.000285	0.000818	CcSEcCtD
Sitaxentan—Liver function test abnormal—Docetaxel—skin cancer	0.000284	0.000816	CcSEcCtD
Sitaxentan—Vomiting—Vemurafenib—skin cancer	0.000283	0.000812	CcSEcCtD
Sitaxentan—Alopecia—Temozolomide—skin cancer	0.000283	0.000812	CcSEcCtD
Sitaxentan—Dry skin—Docetaxel—skin cancer	0.000282	0.00081	CcSEcCtD
Sitaxentan—Chest pain—Bleomycin—skin cancer	0.000281	0.000807	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Docetaxel—skin cancer	0.000281	0.000807	CcSEcCtD
Sitaxentan—Abdominal pain upper—Docetaxel—skin cancer	0.000281	0.000807	CcSEcCtD
Sitaxentan—Rash—Vemurafenib—skin cancer	0.000281	0.000806	CcSEcCtD
Sitaxentan—Mental disorder—Temozolomide—skin cancer	0.00028	0.000805	CcSEcCtD
Sitaxentan—Dermatitis—Vemurafenib—skin cancer	0.00028	0.000805	CcSEcCtD
Sitaxentan—Hypersensitivity—Imiquimod—skin cancer	0.00028	0.000803	CcSEcCtD
Sitaxentan—Headache—Vemurafenib—skin cancer	0.000279	0.0008	CcSEcCtD
Sitaxentan—Malnutrition—Temozolomide—skin cancer	0.000279	0.0008	CcSEcCtD
Sitaxentan—Breast disorder—Docetaxel—skin cancer	0.000278	0.000798	CcSEcCtD
Sitaxentan—Discomfort—Bleomycin—skin cancer	0.000278	0.000798	CcSEcCtD
Sitaxentan—Malaise—Dactinomycin—skin cancer	0.000278	0.000798	CcSEcCtD
Sitaxentan—Cramp muscle—Docetaxel—skin cancer	0.000277	0.000796	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000277	0.000796	CcSEcCtD
Sitaxentan—Leukopenia—Dactinomycin—skin cancer	0.000276	0.000792	CcSEcCtD
Sitaxentan—Asthenia—Imiquimod—skin cancer	0.000272	0.000782	CcSEcCtD
Sitaxentan—Confusional state—Bleomycin—skin cancer	0.000272	0.00078	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000271	0.000779	CcSEcCtD
Sitaxentan—Oedema—Bleomycin—skin cancer	0.00027	0.000774	CcSEcCtD
Sitaxentan—Infection—Bleomycin—skin cancer	0.000268	0.000769	CcSEcCtD
Sitaxentan—Nausea—Vemurafenib—skin cancer	0.000264	0.000759	CcSEcCtD
Sitaxentan—Thrombocytopenia—Bleomycin—skin cancer	0.000264	0.000758	CcSEcCtD
Sitaxentan—Tremor—Temozolomide—skin cancer	0.000261	0.00075	CcSEcCtD
Sitaxentan—Alopecia—Fluorouracil—skin cancer	0.000261	0.000748	CcSEcCtD
Sitaxentan—Diarrhoea—Imiquimod—skin cancer	0.00026	0.000745	CcSEcCtD
Sitaxentan—Discomfort—Dactinomycin—skin cancer	0.000259	0.000744	CcSEcCtD
Sitaxentan—Angina pectoris—Docetaxel—skin cancer	0.000259	0.000744	CcSEcCtD
Sitaxentan—Ill-defined disorder—Temozolomide—skin cancer	0.000259	0.000742	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000258	0.0115	CbGpPWpGaD
Sitaxentan—Anaemia—Temozolomide—skin cancer	0.000258	0.000739	CcSEcCtD
Sitaxentan—Anorexia—Bleomycin—skin cancer	0.000257	0.000738	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—MC1R—skin cancer	0.000256	0.0114	CbGpPWpGaD
Sitaxentan—Agitation—Temozolomide—skin cancer	0.000256	0.000735	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—SHH—skin cancer	0.000255	0.0113	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PTCH2—skin cancer	0.000254	0.0113	CbGpPWpGaD
Sitaxentan—Pancytopenia—Docetaxel—skin cancer	0.000253	0.000725	CcSEcCtD
Sitaxentan—Hypotension—Bleomycin—skin cancer	0.000252	0.000723	CcSEcCtD
Sitaxentan—Oedema—Dactinomycin—skin cancer	0.000251	0.000722	CcSEcCtD
Sitaxentan—Malaise—Temozolomide—skin cancer	0.000251	0.000721	CcSEcCtD
Sitaxentan—Dizziness—Imiquimod—skin cancer	0.000251	0.00072	CcSEcCtD
Sitaxentan—Vertigo—Temozolomide—skin cancer	0.00025	0.000719	CcSEcCtD
Sitaxentan—Infection—Dactinomycin—skin cancer	0.00025	0.000717	CcSEcCtD
Sitaxentan—Leukopenia—Temozolomide—skin cancer	0.000249	0.000716	CcSEcCtD
Sitaxentan—Thrombocytopenia—Dactinomycin—skin cancer	0.000246	0.000707	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—SMO—skin cancer	0.000242	0.0107	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—PTCH1—skin cancer	0.000242	0.0107	CbGpPWpGaD
Sitaxentan—Vomiting—Imiquimod—skin cancer	0.000241	0.000693	CcSEcCtD
Sitaxentan—Weight decreased—Docetaxel—skin cancer	0.000241	0.000691	CcSEcCtD
Sitaxentan—Anorexia—Dactinomycin—skin cancer	0.00024	0.000688	CcSEcCtD
Sitaxentan—EDNRB—Endothelins—HRAS—skin cancer	0.00024	0.0106	CbGpPWpGaD
Sitaxentan—Rash—Imiquimod—skin cancer	0.000239	0.000687	CcSEcCtD
Sitaxentan—Dermatitis—Imiquimod—skin cancer	0.000239	0.000686	CcSEcCtD
Sitaxentan—Headache—Imiquimod—skin cancer	0.000238	0.000683	CcSEcCtD
Sitaxentan—Anaemia—Fluorouracil—skin cancer	0.000237	0.000681	CcSEcCtD
Sitaxentan—Infestation NOS—Docetaxel—skin cancer	0.000237	0.000681	CcSEcCtD
Sitaxentan—Infestation—Docetaxel—skin cancer	0.000237	0.000681	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000236	0.000676	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—PTGER4—skin cancer	0.000235	0.0104	CbGpPWpGaD
Sitaxentan—Discomfort—Temozolomide—skin cancer	0.000234	0.000673	CcSEcCtD
Sitaxentan—Decreased appetite—Bleomycin—skin cancer	0.000234	0.000673	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Docetaxel—skin cancer	0.000234	0.000671	CcSEcCtD
Sitaxentan—Renal failure—Docetaxel—skin cancer	0.000233	0.000669	CcSEcCtD
Sitaxentan—Myocardial infarction—Docetaxel—skin cancer	0.000232	0.000667	CcSEcCtD
Sitaxentan—Dry mouth—Temozolomide—skin cancer	0.000232	0.000666	CcSEcCtD
Sitaxentan—Jaundice—Docetaxel—skin cancer	0.000231	0.000664	CcSEcCtD
Sitaxentan—Stomatitis—Docetaxel—skin cancer	0.000231	0.000664	CcSEcCtD
Sitaxentan—Pain—Bleomycin—skin cancer	0.000231	0.000662	CcSEcCtD
Sitaxentan—Conjunctivitis—Docetaxel—skin cancer	0.00023	0.000662	CcSEcCtD
Sitaxentan—Leukopenia—Fluorouracil—skin cancer	0.00023	0.00066	CcSEcCtD
Sitaxentan—Confusional state—Temozolomide—skin cancer	0.000229	0.000658	CcSEcCtD
Sitaxentan—Oedema—Temozolomide—skin cancer	0.000227	0.000653	CcSEcCtD
Sitaxentan—Infection—Temozolomide—skin cancer	0.000226	0.000649	CcSEcCtD
Sitaxentan—Nausea—Imiquimod—skin cancer	0.000225	0.000647	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Docetaxel—skin cancer	0.000224	0.000644	CcSEcCtD
Sitaxentan—Epistaxis—Docetaxel—skin cancer	0.000224	0.000642	CcSEcCtD
Sitaxentan—Nervous system disorder—Temozolomide—skin cancer	0.000223	0.00064	CcSEcCtD
Sitaxentan—Thrombocytopenia—Temozolomide—skin cancer	0.000223	0.000639	CcSEcCtD
Sitaxentan—Feeling abnormal—Bleomycin—skin cancer	0.000222	0.000638	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000221	0.00982	CbGpPWpGaD
Sitaxentan—Skin disorder—Temozolomide—skin cancer	0.000221	0.000634	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—RHOU—skin cancer	0.00022	0.00977	CbGpPWpGaD
Sitaxentan—Chest pain—Fluorouracil—skin cancer	0.000219	0.000628	CcSEcCtD
Sitaxentan—Decreased appetite—Dactinomycin—skin cancer	0.000219	0.000628	CcSEcCtD
Sitaxentan—Fatigue—Dactinomycin—skin cancer	0.000217	0.000622	CcSEcCtD
Sitaxentan—Anorexia—Temozolomide—skin cancer	0.000217	0.000622	CcSEcCtD
Sitaxentan—Discomfort—Fluorouracil—skin cancer	0.000216	0.00062	CcSEcCtD
Sitaxentan—Pain—Dactinomycin—skin cancer	0.000215	0.000617	CcSEcCtD
Sitaxentan—Urticaria—Bleomycin—skin cancer	0.000214	0.000615	CcSEcCtD
Sitaxentan—Haemoglobin—Docetaxel—skin cancer	0.000214	0.000614	CcSEcCtD
Sitaxentan—Rhinitis—Docetaxel—skin cancer	0.000213	0.000613	CcSEcCtD
Sitaxentan—Body temperature increased—Bleomycin—skin cancer	0.000213	0.000612	CcSEcCtD
Sitaxentan—Haemorrhage—Docetaxel—skin cancer	0.000213	0.000611	CcSEcCtD
Sitaxentan—Hepatitis—Docetaxel—skin cancer	0.000213	0.000611	CcSEcCtD
Sitaxentan—Confusional state—Fluorouracil—skin cancer	0.000211	0.000607	CcSEcCtD
Sitaxentan—Urinary tract disorder—Docetaxel—skin cancer	0.00021	0.000604	CcSEcCtD
Sitaxentan—Oedema peripheral—Docetaxel—skin cancer	0.00021	0.000602	CcSEcCtD
Sitaxentan—Oedema—Fluorouracil—skin cancer	0.00021	0.000602	CcSEcCtD
Sitaxentan—Urethral disorder—Docetaxel—skin cancer	0.000209	0.000599	CcSEcCtD
Sitaxentan—Infection—Fluorouracil—skin cancer	0.000208	0.000598	CcSEcCtD
Sitaxentan—Feeling abnormal—Dactinomycin—skin cancer	0.000207	0.000595	CcSEcCtD
Sitaxentan—Insomnia—Temozolomide—skin cancer	0.000206	0.000591	CcSEcCtD
Sitaxentan—Nervous system disorder—Fluorouracil—skin cancer	0.000205	0.00059	CcSEcCtD
Sitaxentan—Thrombocytopenia—Fluorouracil—skin cancer	0.000205	0.000589	CcSEcCtD
Sitaxentan—Visual impairment—Docetaxel—skin cancer	0.000205	0.000589	CcSEcCtD
Sitaxentan—Tachycardia—Fluorouracil—skin cancer	0.000204	0.000587	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—MC1R—skin cancer	0.000202	0.00898	CbGpPWpGaD
Sitaxentan—Somnolence—Temozolomide—skin cancer	0.000202	0.00058	CcSEcCtD
Sitaxentan—Dyspepsia—Temozolomide—skin cancer	0.0002	0.000575	CcSEcCtD
Sitaxentan—Anorexia—Fluorouracil—skin cancer	0.0002	0.000573	CcSEcCtD
Sitaxentan—Eye disorder—Docetaxel—skin cancer	0.000199	0.000571	CcSEcCtD
Sitaxentan—Body temperature increased—Dactinomycin—skin cancer	0.000199	0.000571	CcSEcCtD
Sitaxentan—Hypersensitivity—Bleomycin—skin cancer	0.000199	0.00057	CcSEcCtD
Sitaxentan—Decreased appetite—Temozolomide—skin cancer	0.000198	0.000568	CcSEcCtD
Sitaxentan—Flushing—Docetaxel—skin cancer	0.000198	0.000567	CcSEcCtD
Sitaxentan—Cardiac disorder—Docetaxel—skin cancer	0.000198	0.000567	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Temozolomide—skin cancer	0.000196	0.000564	CcSEcCtD
Sitaxentan—Fatigue—Temozolomide—skin cancer	0.000196	0.000563	CcSEcCtD
Sitaxentan—Hypotension—Fluorouracil—skin cancer	0.000196	0.000562	CcSEcCtD
Sitaxentan—Constipation—Temozolomide—skin cancer	0.000194	0.000558	CcSEcCtD
Sitaxentan—Pain—Temozolomide—skin cancer	0.000194	0.000558	CcSEcCtD
Sitaxentan—Asthenia—Bleomycin—skin cancer	0.000193	0.000555	CcSEcCtD
Sitaxentan—Angiopathy—Docetaxel—skin cancer	0.000193	0.000554	CcSEcCtD
Sitaxentan—Immune system disorder—Docetaxel—skin cancer	0.000192	0.000552	CcSEcCtD
Sitaxentan—Mediastinal disorder—Docetaxel—skin cancer	0.000192	0.000551	CcSEcCtD
Sitaxentan—Insomnia—Fluorouracil—skin cancer	0.00019	0.000544	CcSEcCtD
Sitaxentan—Alopecia—Docetaxel—skin cancer	0.000188	0.00054	CcSEcCtD
Sitaxentan—Feeling abnormal—Temozolomide—skin cancer	0.000187	0.000538	CcSEcCtD
Sitaxentan—Mental disorder—Docetaxel—skin cancer	0.000186	0.000535	CcSEcCtD
Sitaxentan—Somnolence—Fluorouracil—skin cancer	0.000186	0.000535	CcSEcCtD
Sitaxentan—Malnutrition—Docetaxel—skin cancer	0.000185	0.000532	CcSEcCtD
Sitaxentan—Hypersensitivity—Dactinomycin—skin cancer	0.000185	0.000532	CcSEcCtD
Sitaxentan—Dyspepsia—Fluorouracil—skin cancer	0.000184	0.00053	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—MC1R—skin cancer	0.000184	0.00815	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—SHH—skin cancer	0.000183	0.0081	CbGpPWpGaD
Sitaxentan—Decreased appetite—Fluorouracil—skin cancer	0.000182	0.000523	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—PTCH2—skin cancer	0.000182	0.00807	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000181	0.000519	CcSEcCtD
Sitaxentan—Urticaria—Temozolomide—skin cancer	0.000181	0.000519	CcSEcCtD
Sitaxentan—Asthenia—Dactinomycin—skin cancer	0.00018	0.000518	CcSEcCtD
Sitaxentan—Body temperature increased—Temozolomide—skin cancer	0.00018	0.000516	CcSEcCtD
Sitaxentan—Pain—Fluorouracil—skin cancer	0.000179	0.000514	CcSEcCtD
Sitaxentan—Muscle spasms—Docetaxel—skin cancer	0.000178	0.000511	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—SMO—skin cancer	0.000173	0.00768	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—PTCH1—skin cancer	0.000173	0.00768	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Fluorouracil—skin cancer	0.000173	0.000496	CcSEcCtD
Sitaxentan—Diarrhoea—Dactinomycin—skin cancer	0.000172	0.000494	CcSEcCtD
Sitaxentan—EDNRA—Endothelins—HRAS—skin cancer	0.000171	0.00761	CbGpPWpGaD
Sitaxentan—Vomiting—Bleomycin—skin cancer	0.000171	0.000492	CcSEcCtD
Sitaxentan—Anaemia—Docetaxel—skin cancer	0.000171	0.000492	CcSEcCtD
Sitaxentan—Rash—Bleomycin—skin cancer	0.00017	0.000488	CcSEcCtD
Sitaxentan—Dermatitis—Bleomycin—skin cancer	0.00017	0.000488	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—PTGER4—skin cancer	0.000169	0.00748	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Temozolomide—skin cancer	0.000168	0.000481	CcSEcCtD
Sitaxentan—Urticaria—Fluorouracil—skin cancer	0.000166	0.000478	CcSEcCtD
Sitaxentan—Leukopenia—Docetaxel—skin cancer	0.000166	0.000476	CcSEcCtD
Sitaxentan—Body temperature increased—Fluorouracil—skin cancer	0.000166	0.000476	CcSEcCtD
Sitaxentan—Asthenia—Temozolomide—skin cancer	0.000163	0.000468	CcSEcCtD
Sitaxentan—Nausea—Bleomycin—skin cancer	0.00016	0.00046	CcSEcCtD
Sitaxentan—Vomiting—Dactinomycin—skin cancer	0.00016	0.000459	CcSEcCtD
Sitaxentan—Rash—Dactinomycin—skin cancer	0.000159	0.000455	CcSEcCtD
Sitaxentan—Chest pain—Docetaxel—skin cancer	0.000158	0.000453	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000157	0.00045	CcSEcCtD
Sitaxentan—Diarrhoea—Temozolomide—skin cancer	0.000156	0.000447	CcSEcCtD
Sitaxentan—Hypersensitivity—Fluorouracil—skin cancer	0.000154	0.000443	CcSEcCtD
Sitaxentan—Dry mouth—Docetaxel—skin cancer	0.000154	0.000443	CcSEcCtD
Sitaxentan—Confusional state—Docetaxel—skin cancer	0.000152	0.000438	CcSEcCtD
Sitaxentan—Oedema—Docetaxel—skin cancer	0.000151	0.000434	CcSEcCtD
Sitaxentan—Dizziness—Temozolomide—skin cancer	0.00015	0.000432	CcSEcCtD
Sitaxentan—Infection—Docetaxel—skin cancer	0.00015	0.000431	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—PTCH2—skin cancer	0.00015	0.00666	CbGpPWpGaD
Sitaxentan—Nausea—Dactinomycin—skin cancer	0.000149	0.000429	CcSEcCtD
Sitaxentan—Nervous system disorder—Docetaxel—skin cancer	0.000148	0.000426	CcSEcCtD
Sitaxentan—Thrombocytopenia—Docetaxel—skin cancer	0.000148	0.000425	CcSEcCtD
Sitaxentan—Tachycardia—Docetaxel—skin cancer	0.000148	0.000424	CcSEcCtD
Sitaxentan—Skin disorder—Docetaxel—skin cancer	0.000147	0.000422	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—MC1R—skin cancer	0.000145	0.00643	CbGpPWpGaD
Sitaxentan—Vomiting—Temozolomide—skin cancer	0.000145	0.000415	CcSEcCtD
Sitaxentan—Anorexia—Docetaxel—skin cancer	0.000144	0.000414	CcSEcCtD
Sitaxentan—Rash—Temozolomide—skin cancer	0.000143	0.000412	CcSEcCtD
Sitaxentan—Diarrhoea—Fluorouracil—skin cancer	0.000143	0.000412	CcSEcCtD
Sitaxentan—Dermatitis—Temozolomide—skin cancer	0.000143	0.000411	CcSEcCtD
Sitaxentan—Headache—Temozolomide—skin cancer	0.000142	0.000409	CcSEcCtD
Sitaxentan—Hypotension—Docetaxel—skin cancer	0.000141	0.000406	CcSEcCtD
Sitaxentan—Dizziness—Fluorouracil—skin cancer	0.000139	0.000398	CcSEcCtD
Sitaxentan—Insomnia—Docetaxel—skin cancer	0.000137	0.000393	CcSEcCtD
Sitaxentan—Nausea—Temozolomide—skin cancer	0.000135	0.000388	CcSEcCtD
Sitaxentan—Somnolence—Docetaxel—skin cancer	0.000134	0.000386	CcSEcCtD
Sitaxentan—Vomiting—Fluorouracil—skin cancer	0.000133	0.000382	CcSEcCtD
Sitaxentan—Dyspepsia—Docetaxel—skin cancer	0.000133	0.000382	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—PTGER4—skin cancer	0.000133	0.00591	CbGpPWpGaD
Sitaxentan—Rash—Fluorouracil—skin cancer	0.000132	0.000379	CcSEcCtD
Sitaxentan—Dermatitis—Fluorouracil—skin cancer	0.000132	0.000379	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—MC1R—skin cancer	0.000132	0.00584	CbGpPWpGaD
Sitaxentan—Decreased appetite—Docetaxel—skin cancer	0.000131	0.000377	CcSEcCtD
Sitaxentan—Headache—Fluorouracil—skin cancer	0.000131	0.000377	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—SHH—skin cancer	0.000131	0.00581	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Docetaxel—skin cancer	0.000131	0.000375	CcSEcCtD
Sitaxentan—Fatigue—Docetaxel—skin cancer	0.00013	0.000374	CcSEcCtD
Sitaxentan—Constipation—Docetaxel—skin cancer	0.000129	0.000371	CcSEcCtD
Sitaxentan—Pain—Docetaxel—skin cancer	0.000129	0.000371	CcSEcCtD
Sitaxentan—Feeling abnormal—Docetaxel—skin cancer	0.000125	0.000358	CcSEcCtD
Sitaxentan—Nausea—Fluorouracil—skin cancer	0.000124	0.000357	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—SMO—skin cancer	0.000124	0.00551	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PTCH1—skin cancer	0.000124	0.00551	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000123	0.00544	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PTGER4—skin cancer	0.000121	0.00536	CbGpPWpGaD
Sitaxentan—Body temperature increased—Docetaxel—skin cancer	0.00012	0.000343	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—GLI2—skin cancer	0.000114	0.00505	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Docetaxel—skin cancer	0.000111	0.00032	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—MC1R—skin cancer	0.000109	0.00482	CbGpPWpGaD
Sitaxentan—Asthenia—Docetaxel—skin cancer	0.000109	0.000312	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PTCH2—skin cancer	0.000107	0.00477	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—GLI1—skin cancer	0.000107	0.00475	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000106	0.00468	CbGpPWpGaD
Sitaxentan—Diarrhoea—Docetaxel—skin cancer	0.000103	0.000297	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—SUFU—skin cancer	0.000101	0.0045	CbGpPWpGaD
Sitaxentan—Dizziness—Docetaxel—skin cancer	0.0001	0.000287	CcSEcCtD
Sitaxentan—Vomiting—Docetaxel—skin cancer	9.62e-05	0.000276	CcSEcCtD
Sitaxentan—Rash—Docetaxel—skin cancer	9.54e-05	0.000274	CcSEcCtD
Sitaxentan—Dermatitis—Docetaxel—skin cancer	9.53e-05	0.000274	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—PTGER4—skin cancer	9.52e-05	0.00423	CbGpPWpGaD
Sitaxentan—Headache—Docetaxel—skin cancer	9.47e-05	0.000272	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—SHH—skin cancer	9.37e-05	0.00416	CbGpPWpGaD
Sitaxentan—Nausea—Docetaxel—skin cancer	8.98e-05	0.000258	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	8.97e-05	0.00398	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PTCH1—skin cancer	8.88e-05	0.00394	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—SMO—skin cancer	8.88e-05	0.00394	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	8.78e-05	0.00389	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PTGER4—skin cancer	8.65e-05	0.00384	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	8.59e-05	0.00381	CbGpPWpGaD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—PTGS2—skin cancer	8.55e-05	0.00379	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GLI2—skin cancer	8.14e-05	0.00361	CbGpPWpGaD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	7.79e-05	0.00346	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MC1R—skin cancer	7.77e-05	0.00345	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SHH—skin cancer	7.74e-05	0.00343	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—RASA1—skin cancer	7.69e-05	0.00341	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GLI1—skin cancer	7.66e-05	0.0034	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	7.55e-05	0.00335	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SMO—skin cancer	7.33e-05	0.00325	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTCH1—skin cancer	7.33e-05	0.00325	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SUFU—skin cancer	7.26e-05	0.00322	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTGER4—skin cancer	7.14e-05	0.00317	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	6.42e-05	0.00285	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	6.4e-05	0.00284	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—FOXO4—skin cancer	6.31e-05	0.0028	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	6.15e-05	0.00273	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	5.84e-05	0.00259	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SHH—skin cancer	5.54e-05	0.00246	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RASA1—skin cancer	5.5e-05	0.00244	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTCH1—skin cancer	5.25e-05	0.00233	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SMO—skin cancer	5.25e-05	0.00233	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTGER4—skin cancer	5.11e-05	0.00227	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—FOXO4—skin cancer	4.51e-05	0.002	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TERT—skin cancer	4.21e-05	0.00187	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—NRAS—skin cancer	3.55e-05	0.00157	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—BRAF—skin cancer	3.34e-05	0.00148	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—KRAS—skin cancer	3.05e-05	0.00136	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TERT—skin cancer	3.01e-05	0.00134	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PLIN2—skin cancer	2.85e-05	0.00127	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PLIN2—skin cancer	2.6e-05	0.00115	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—HRAS—skin cancer	2.6e-05	0.00115	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—NRAS—skin cancer	2.54e-05	0.00113	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL6—skin cancer	2.48e-05	0.0011	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—BRAF—skin cancer	2.39e-05	0.00106	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CSPG4—skin cancer	2.3e-05	0.00102	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—KRAS—skin cancer	2.19e-05	0.00097	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NRAS—skin cancer	2.1e-05	0.00093	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CSPG4—skin cancer	2.1e-05	0.00093	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—HRAS—skin cancer	1.86e-05	0.000824	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KRAS—skin cancer	1.8e-05	0.000801	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL6—skin cancer	1.78e-05	0.000789	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PLIN2—skin cancer	1.71e-05	0.000761	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—skin cancer	1.6e-05	0.000712	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ENO2—skin cancer	1.56e-05	0.000693	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HRAS—skin cancer	1.53e-05	0.000681	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NRAS—skin cancer	1.5e-05	0.000666	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL6—skin cancer	1.47e-05	0.000651	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ENO2—skin cancer	1.42e-05	0.000632	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CSPG4—skin cancer	1.38e-05	0.000613	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KRAS—skin cancer	1.29e-05	0.000573	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.22e-05	0.000542	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—skin cancer	1.15e-05	0.000509	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.11e-05	0.000494	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HRAS—skin cancer	1.1e-05	0.000487	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6—skin cancer	1.05e-05	0.000466	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ENO2—skin cancer	9.39e-06	0.000417	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ERCC2—skin cancer	9.07e-06	0.000403	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ERCC2—skin cancer	8.27e-06	0.000367	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ERCC2—skin cancer	5.46e-06	0.000242	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS2—skin cancer	5.44e-06	0.000241	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS2—skin cancer	4.96e-06	0.00022	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS2—skin cancer	3.27e-06	0.000145	CbGpPWpGaD
